Enhanced and stabilized my mood I will order everything I need from VITAstir from now on
A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC
Click here to view a video tutorial covering frequently asked questions regarding ELISA workflows
The slight difference between the Adjusted R 2 and Predicted R 2 values suggests that the model is reliable and can be confidently used for designing future experiments
IUBMB Life 66(3):212219 Ichihara K, Hosogaya S, Okutani R, Yoshimoto S, Itoh K, Kameko M, Kayamori Y, Takagi Y, Nakano Y, Haga R, Motonaga H (2006) Protocols of determining limits of detection and limits of quantitation for quantitative analytical methods
If your answer is no then you are at the right place